Ena Respiratory is a biotech company specializing in the development of a first-in-class prophylactic intranasal antiviral innate immunomodulator, INNA-051, aimed at preventing respiratory infections such as COVID-19 and influenza.

Ena Respiratory

Folklore is a venture capital firm that supports Australian and New Zealand tech founders and their teams.

Folklore

Brandon Capital is Australasia's leading life science venture capital firm, with a strong global presence supported by key partnerships and team members across the US and UK. Through collaboration and investment, we transform promising medical research breakthroughs into medical therapies that improve patients lives. We have supported more than 50 start-up companies to date, the majority of which were founded by us in collaboration with the inventor and their research institutes. From early-stage seed investment through to expansion capital, Brandon Capital supports life science companies from proof-of-concept through to commercialisation.

For more information about Brandon Capital, visit www.brandoncapital.vc

Brandon Capital

📣Certa Therapeutics is expanding and seeking an experienced Executive Assistant to support the team's growth plans.

The role will support the CEO and the Executive Team across a broad range of administrative and office management duties, which may vary from routine to complex in nature.

And you'd be joining a company whose commitment to science and patients shines through in everything they do. 

Link below if you or someone you know are interested in learning more 👇🏾

https://lnkd.in/gc7mAqCr

This International Women’s Day, we’re sharing copies of Good Night Stories For Rebel Girls with community groups and Brandon BioCatalyst members.
 
Our decision was sparked by a recent Australian study that showed that by age 7 to 8, 22% of boys aspire to STEM careers, and only 6% of girls share the same aspiration*. 
 
Whilst this year’s theme is investing in women, we wanted to do something that invested in inspiration.
 
Some of the incredible Brandon women who trained as scientists, have personalised each book with a note about their careers, which we hope will inspire the children who read them to pursue a career in STEM.
 
But this gesture isn’t just about inspiring the next generation of scientists; it's also about broadening horizons and challenging stereotypes.
 
So, if the girls or boys who read these books discover a non-STEM career outside their current realm of opportunity or picture a woman when asked to think of a scientist, that would be awesome, too.
 
#InternationalWomensDay #STEM #RepresentationMatters #Empowerment

The Queensland Translation and Commercialisation Skills Gap Program kicked off last week with Brandon UK Venture Partner Dr Roberto Solari and Investment Analyst Dr Melissa Byrne leading seminars introducing the Target Product Profile and the importance of picking the right target.

Here are some key takeouts for research scientists and biotech entrepreneurs from people in the room:

🧭 It's important to acknowledge that failure is common in drug development, predominantly due to efficacy issues.  

🧭 Carefully evaluate potential targets. Thoroughly examine mechanisms of action, related pathways, available modulators, and effective testing strategies.

🧭 Begin with the end in mind. Consider the target product profile (TPP) and envision the pathway to reaching patients, mapping the necessary steps from clinical to preclinical stages and target discovery.

🧭 Identify the key data points for validating target viability. They will guide future investment decisions and shape the trajectory of drug development.

Link to register for the next seminar that will cover how to turn research discoveries into drug development programs 👇🏾

https://lnkd.in/gSPhatz6

Thanks to the Queensland Government Department of State Development and Infrastructure for supporting the program.

💻🍎🩺 $1M Digital Health Technology Grants

Do you have a ‘game changer’ idea that will promote improved equity of access to primary care?

Will your idea use digital health technology to support an innovative model of care?

The PHN is investing $1 million in innovative solutions that harness digital health technology to provide improved models of care within the primary care sector.

Think you have a ‘game changer’? Click on the link below to learn more and apply. We look forward to receiving your submission.

🔗 https://lnkd.in/g5VKhSpd

#grants #healthgrant #digitalhealth

Metric
Company Name	Ena Respiratory	Folklore
Symbol
MSH ID	VC:BRANDONCAPITAL	VC:FOLKLORE
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Financial Services & Finance
Industry	Biotechnology	Venture Capital
Country	AU	AU
Stage
Employee Count	45
Website	brandoncapital.vc	folklore.vc
LinkedIn	brandon-capital
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	10.36
28-Day Growth Score	16.39
90-Day Growth Score	14.09
365-Day Growth Score	13.03

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

VC:BRANDONCAPITAL

Ena Respiratory

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue